Ventyx Biosciences

At a special meeting, Ventyx Biosciences shareholders voted to merge with Eli Lilly, making Ventyx a wholly owned subsidiary of Eli Lilly. The main proposal received 44,176,785 yes votes out of 45,810,746 shares present. Eli Lilly is offering $14 per share; the deal is valued at about $1.2 billion and is expected to close in the first half of 2026. Compensation arrangements for executives related to the takeover were also approved; analysts reacted with downgrades and adjusted price targets to the takeover price. » More on de.investing.com

Ventyx shares fell about 10% after the company announced it will postpone publication of the interim results from its phase‑2 study in recurrent pericarditis to the first quarter of 2026. The company plans to present topline data during an R&D day in Q1/2026 and intends to integrate a new once‑daily formulation and dose‑finding data into the ongoing study. Ventyx is expanding the study to Canada, the EU and the UK, extending the extension phase to 24 weeks, keeping the primary endpoint at six weeks, and appointing two experts to its advisory board. » More on de.investing.com

Ventyx appointed Mark McKenna and Peter Libby as strategic and clinical advisors, respectively, and is expanding its multicenter phase-2 study of VTX2735 to Canada, the EU and the UK. The company will introduce a once-daily formulation in December, extend follow-up to week 24 while keeping week 6 as the primary endpoint, and now plans to release topline interim analysis results in Q1 2026 at a planned R&D day; Health Canada has approved activation of Canadian sites. Additional news cited positive phase-2 data for VTX3232 and analyst upgrades that could support valuation and partnership opportunities. » More on de.investing.com